38 results on '"Waschki, Benjamin"'
Search Results
2. Spatial characteristics of non-communicable diseases and their associations to social conditions in a large urban cohort in Germany—Results from the Hamburg City Health Study
- Author
-
Andrees, Valerie, primary, Bei der Kellen, Ramona, additional, Augustin, Matthias, additional, Gallinat, Jürgen, additional, Harth, Volker, additional, Hoven, Hanno, additional, Kühn, Simone, additional, Lautenbach, Anne, additional, Magnussen, Christina, additional, Mohr, Nicole, additional, Twerenbold, Raphael, additional, Schäfer, Ines, additional, Waschki, Benjamin, additional, Zyriax, Birgit-Christiane, additional, and Augustin, Jobst, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Cardiovascular predictors of mortality and exacerbations in patients with COPD
- Author
-
Alter, Peter, Lucke, Tanja, Watz, Henrik, Andreas, Stefan, Kahnert, Kathrin, Trudzinski, Franziska C., Speicher, Tim, Söhler, Sandra, Bals, Robert, Waschki, Benjamin, Welte, Tobias, Rabe, Klaus F., Vestbo, Jørgen, Wouters, Emiel F. M., Vogelmeier, Claus F., and Jörres, Rudolf A.
- Published
- 2022
- Full Text
- View/download PDF
4. CAT score single item analysis in patients with COPD: Results from COSYCONET
- Author
-
Stefan, Andreas, Robert, Bals, Jürgen, Behr, Kathrin, Kahnert, Burkhard, Bewig, Roland, Buhl, Ralf, Ewert, Beate, Stubbe, Ficker, Joachim H., Manfred, Gogol, Christian, Grohé, Rainer, Hauck, Matthias, Held, Berthold, Jany, Markus, Henke, Felix, Herth, Gerd, Höffken, Katus Hugo, A., Anne-Marie, Kirsten, Henrik, Watz, Rembert, Koczulla, Klaus, Kenn, Juliane, Kronsbein, Cornelia, Kropf-Sanchen, Christoph, Lange, Peter, Zabel, Michael, Pfeifer, Randerath Winfried, J., Werner, Seeger, Michael, Studnicka, Christian, Taube, Helmut, Teschler, Hartmut, Timmermann, Christian, Virchow J., Claus, Vogelmeier, Ulrich, Wagner, Tobias, Welte, Hubert, Wirtz, Lehnert, Doris, Struck, Birte, Krabbe, Lenka, Arikan, Barbara, Tobias, Julia, Speth, Kornelia, Pieper, Jeanette, Gleiniger, Margret, Markworth, Britta, Hinz, Zaklina, Burmann, Ellen, Wons, Katrin, Rieber, Ulrike, Schaufler, Beate, Schwedler, Katrin, Michalewski, Sabine, Rohweder, Sonja, Berger, Patricia, Schottel, Diana, Janke, Vivien, Untsch, Rosalie, Graf, Jana, Reichel, Anita, Weiß, Gertraud, Traugott, Erich, Kietzmann, Ilona, Schrade-Illmann, Michaela, Polte, Beate, Hübner, Gudrun, Marietta von Siemens, Sarah, Alter, Peter, Lutter, Johanna I., Kauczor, Hans-Ulrich, Jobst, Bertram, Bals, Robert, Trudzinski, Franziska C., Söhler, Sandra, Behr, Jürgen, Watz, Henrik, Waschki, Benjamin, Bewig, Burkhard, Jones, Paul W., Welte, Tobias, Vogelmeier, Claus F., Jörres, Rudolf A., and Kahnert, Kathrin
- Published
- 2019
- Full Text
- View/download PDF
5. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling
- Author
-
Alter, Peter, Watz, Henrik, Kahnert, Kathrin, Pfeifer, Michael, Randerath, Winfried J., Andreas, Stefan, Waschki, Benjamin, Kleibrink, Björn E., Welte, Tobias, Bals, Robert, Schulz, Holger, Biertz, Frank, Young, David, Vogelmeier, Claus F., and Jörres, Rudolf A.
- Published
- 2018
- Full Text
- View/download PDF
6. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study
- Author
-
Abdo, Mustafa, Watz, Henrik, Veith, Vera, Kirsten, Anne-Marie, Biller, Heike, Pedersen, Frauke, von Mutius, Erika, Kopp, Matthias V., Hansen, Gesine, Waschki, Benjamin, Rabe, Klaus F., Trinkmann, Frederik, and Bahmer, Thomas
- Published
- 2020
- Full Text
- View/download PDF
7. Consequences of chronic kidney disease in chronic obstructive pulmonary disease
- Author
-
Trudzinski, Franziska C., Alqudrah, Mohamad, Omlor, Albert, Zewinger, Stephen, Fliser, Danilo, Speer, Timotheus, Seiler, Frederik, Biertz, Frank, Koch, Armin, Vogelmeier, Claus, Welte, Tobias, Watz, Henrik, Waschki, Benjamin, Fähndrich, Sebastian, Jörres, Rudolf, Bals, Robert, and on behalf of the German COSYCONET consortium
- Published
- 2019
- Full Text
- View/download PDF
8. Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers : Results of the COSYCONET Cohort
- Author
-
Lutter,Johanna I, Jörres,Rudolf A, Welte,Tobias, Watz,Henrik, Waschki,Benjamin, Alter,Peter, Trudzinski,Franziska C, Ohlander,Johan, Behr,Jürgen, Bals,Robert, Studnicka,Michael, Holle,Rolf, Vogelmeier,Claus F, and Kahnert,Kathrin
- Subjects
socioeconomic status ,education ,never-smoker ,COPD ,International Journal of Chronic Obstructive Pulmonary Disease - Abstract
Johanna I Lutter,1 Rudolf A Jörres,2 Tobias Welte,3 Henrik Watz,4 Benjamin Waschki,5 Peter Alter,6 Franziska C Trudzinski,7 Johan Ohlander,1,8 Jürgen Behr,9 Robert Bals,10 Michael Studnicka,11 Rolf Holle,12 Claus F Vogelmeier,6 Kathrin Kahnert9 1Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Munich, Germany; 2Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Munich 80336, Germany; 3Department of Pneumology, Hannover Medical School, Hannover 30625, Germany; 4Pulmonary Research Institute at Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf 22927, Germany; 5Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany; 6Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg (UMR), Germany, Member of the German Center for Lung Research (DZL), Marburg 35043, Germany; 7Department of Diagnostic & Interventional Radiology, University Hospital of Heidelberg, Heidelberg, Germany; 8Institute for Risk Assessment Sciences, Utrecht University, Utrecht 3584 CM, Netherlands; 9Department of Internal Medicine V, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, 80336, Germany; 10Department of Internal Medicine V – Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Homburg 66424, Germany; 11Department of Pneumology, Paracelsus Medical University Salzburg, Universitätsklinikum Salzburg, Salzburg 5020, Austria; 12Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Ludwig-Maximilians-University Munich (LMU), Munich 81377, GermanyCorrespondence: Kathrin KahnertDepartment of Internal Medicine V, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Ziemssenstr. 1, Munich 80336, GermanyEmail Kathrin.Kahnert@med.uni-muenchen.deBackground: Beyond smoking, several risk factors for the development of chronic obstructive pulmonary disease (COPD) have been described, among which socioeconomic status including education is of particular interest. We studied the contribution of education to lung function and symptoms relative to smoking in a group of never-smokers with COPD compared to a group of long-time ex-smokers with COPD.Methods: We used baseline data of the COSYCONET cohort, including patients of GOLD grades 1– 4 who were either never-smokers (n=150, age 68.5y, 53.3% female) or ex-smokers (≥ 10 packyears) for at least 10 years (n=616, 68.3y, 29.9% female). Socioeconomic status was analyzed using education level and mortality was assessed over a follow-up period of 4.5 years. Analyses were performed using ANOVA and regression models.Results: Spirometric lung function did not differ between groups, whereas CO diffusing capacity and indicators of lung hyperinflation/air-trapping showed better values in the never-smoker group. In both groups, spirometric lung function depended on the education level, with better values for higher education. Quality of life and 6-MWD were significantly different in never-smokers as well as patients with higher education. Asthma, alpha-1-antitrypsin deficiency, and bronchiectasis were more often reported in never-smokers, and asthma was more often reported in patients with higher education. Higher education was also associated with reduced mortality (hazard ratio 0.46; 95% CI 0.22– 0.98).Conclusion: Overall, in the COSYCONET COPD cohort, differences in functional status between never-smokers and long-time ex-smokers were not large. Compared to that, the dependence on education level was more prominent, with higher education associated with better outcomes, including mortality. These data indicate that non-smoking COPD patients’ socioeconomic factors are relevant and should be taken into account by clinicians.Keywords: COPD, never-smoker, education, socioeconomic status
- Published
- 2022
- Full Text
- View/download PDF
9. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort
- Author
-
von Siemens, Sarah Marietta, Perneczky, Robert, Waschki, Benjamin, Lutter, Johanna I, Welte, Tobias, Jörres, Rudolf A, Kahnert, Kathrin, group, COSYCONET study, Andreas, Stefan, Bals, Robert, Behr, Jürgen, Vogelmeier, Claus F, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Gogol, Manfred, Grohé, Christian, Hauck, Rainer, Held, Matthias, Jany, Berthold, Henke, Markus, Herth, Felix, Höffken, Gerd, Katus, Hugo A, Kirsten, Anne-Marie, Watz, Henrik, Koczulla, Rembert, Kenn, Klaus, Kronsbein, Juliane, Kropf-Sanchen, Cornelia, Lange, Christoph, Kauffmann-Guerrero, Diego, Zabel, Peter, Pfeifer, Michael, Randerath, Winfried J, Seeger, Werner, Studnicka, Michael, Taube, Christian, Teschler, Helmut, Timmermann, Hartmut, Virchow, J Christian, Vogelmeier, Claus, Alter, Peter, Wagner, Ulrich, Wirtz, Hubert, Trudzinski, Franziska C, and Söhler, Sandra
- Subjects
Male ,medicine.medical_specialty ,epidemiology [Cognitive Dysfunction] ,psychology [Pulmonary Disease, Chronic Obstructive] ,Medizin ,Comorbidity ,Cohort Studies ,03 medical and health sciences ,FEV1/FVC ratio ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Cognition ,epidemiology [Pulmonary Disease, Chronic Obstructive] ,Surveys and Questionnaires ,medicine ,Dementia ,Humans ,COPD ,Cognitive Dysfunction ,ddc:610 ,Cognitive skill ,Path analysis (statistics) ,Aged ,lcsh:RC705-779 ,business.industry ,Research ,physiology [Cognition] ,diagnosis [Pulmonary Disease, Chronic Obstructive] ,lcsh:Diseases of the respiratory system ,Middle Aged ,medicine.disease ,Mental Status and Dementia Tests ,humanities ,Cross-Sectional Studies ,Cognitive impairment ,diagnosis [Cognitive Dysfunction] ,030228 respiratory system ,Cohort ,Physical therapy ,Female ,psychology [Cognitive Dysfunction] ,business ,030217 neurology & neurosurgery ,Cognitive load - Abstract
Alterations of cognitive functions have been described in COPD. Our study aimed to disentangle the relationship between the degree of cognitive function and COPD characteristics including quality of life (QoL).Data from 1969 COPD patients of the COSYCONET cohort (GOLD grades 1–4; 1216 male/ 753 female; mean (SD) age 64.9 ± 8.4 years) were analysed using regression and path analysis. The DemTect screening tool was used to measure cognitive function, and the St. George‘s respiratory questionnaire (SGRQ) to assess disease-specific QoL.DemTect scores were =60 years of age. For statistical reasons, we used the average of both algorithms independent of age in all subsequent analyses. The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. Conversely, the SGRQ impact score was independently associated with 6-MWD, FVC, mMRC and DemTect. These results were combined into a path analysis model to account for direct and indirect effects. The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. Furthermore, a reduction in cognitive capacity was associated with reduced disease-specific quality of life. As a potential clinical implication of this work, we suggest to screen especially patients with low oxygen content and low 6-MWD for cognitive impairment.
- Published
- 2022
- Full Text
- View/download PDF
10. Physical and Mental Recovery after Aortic Valve Surgery in Non-Elderly Patients: Native Valve-Preserving Surgery vs. Prosthetic Valve Replacement.
- Author
-
Holst, Theresa, Petersen, Johannes, Friedrich, Sarah, Waschki, Benjamin, Sinning, Christoph, Rybczynski, Meike, Reichenspurner, Hermann, and Girdauskas, Evaldas
- Published
- 2023
- Full Text
- View/download PDF
11. Hyponatremia as prognostic factor in small cell lung cancer – A retrospective single institution analysis
- Author
-
Hermes, Andreas, Waschki, Benjamin, and Reck, Martin
- Published
- 2012
- Full Text
- View/download PDF
12. Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study
- Author
-
Waschki, Benjamin, Spruit, Martijn A., Watz, Henrik, Albert, Paul S., Shrikrishna, Dinesh, Groenen, Miriam, Smith, Cayley, Man, William D.-C., Tal-Singer, Ruth, Edwards, Lisa D., Calverley, Peter M.A., Magnussen, Helgo, Polkey, Michael I., and Wouters, Emiel F.M.
- Published
- 2012
- Full Text
- View/download PDF
13. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme
- Author
-
Petersen, Elina Larissa, primary, Goßling, Alina, additional, Adam, Gerhard, additional, Aepfelbacher, Martin, additional, Behrendt, Christian-Alexander, additional, Cavus, Ersin, additional, Cheng, Bastian, additional, Fischer, Nicole, additional, Gallinat, Jürgen, additional, Kühn, Simone, additional, Gerloff, Christian, additional, Koch-Gromus, Uwe, additional, Härter, Martin, additional, Hanning, Uta, additional, Huber, Tobias B., additional, Kluge, Stefan, additional, Knobloch, Johannes K., additional, Kuta, Piotr, additional, Schmidt-Lauber, Christian, additional, Lütgehetmann, Marc, additional, Magnussen, Christina, additional, Mayer, Carola, additional, Muellerleile, Kai, additional, Münch, Julia, additional, Nägele, Felix Leonard, additional, Petersen, Marvin, additional, Renné, Thomas, additional, Riedl, Katharina Alina, additional, Rimmele, David Leander, additional, Schäfer, Ines, additional, Schulz, Holger, additional, Tahir, Enver, additional, Waschki, Benjamin, additional, Wenzel, Jan-Per, additional, Zeller, Tanja, additional, Ziegler, Andreas, additional, Thomalla, Götz, additional, Twerenbold, Raphael, additional, and Blankenberg, Stefan, additional
- Published
- 2022
- Full Text
- View/download PDF
14. The Relevance of Small Airway Dysfunction in Asthma with Nocturnal Symptoms
- Author
-
Abdo, Mustafa, primary, Trinkmann, Frederik, additional, Kirsten, Anne-Marie, additional, Biller, Heike, additional, Pedersen, Frauke, additional, Waschki, Benjamin, additional, Von Mutius, Erika, additional, Kopp, Matthias Volkmar, additional, Hansen, Gesine, additional, Rabe, Klaus F, additional, Bahmer, Thomas, additional, and Watz, Henrik, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease
- Author
-
Waschki, Benjamin, Kirsten, Anne M., Holz, Olaf, Mueller, Kai-Christian, Schaper, Miriam, Sack, Anna-Lena, Meyer, Thorsten, Rabe, Klaus F., Magnussen, Helgo, and Watz, Henrik
- Published
- 2015
- Full Text
- View/download PDF
16. Persistent Uncontrolled Asthma: Long-Term Impact on Physical Activity and Body Composition
- Author
-
Abdo, Mustafa, primary, Waschki, Benjamin, additional, Kirsten, Anne-Marie, additional, Trinkmann, Frederik, additional, Biller, Heike, additional, Herzmann, Christian, additional, von Mutius, Erika, additional, Kopp, Matthias, additional, Hansen, Gesine, additional, Rabe, Klaus F, additional, Bahmer, Thomas, additional, and Watz, Henrik, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort
- Author
-
Lutter, Johanna I, primary, Jörres, Rudolf A, additional, Welte, Tobias, additional, Watz, Henrik, additional, Waschki, Benjamin, additional, Alter, Peter, additional, Trudzinski, Franziska C, additional, Ohlander, Johan, additional, Behr, Jürgen, additional, Bals, Robert, additional, Studnicka, Michael, additional, Holle, Rolf, additional, Vogelmeier, Claus F, additional, and Kahnert, Kathrin, additional
- Published
- 2020
- Full Text
- View/download PDF
18. Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort
- Author
-
Holz, Olaf, primary, Waschki, Benjamin, additional, Watz, Henrik, additional, Kirsten, Anne, additional, Abdo, Mustafa, additional, Pedersen, Frauke, additional, Weckmann, Markus, additional, Fuchs, Oliver, additional, Dittrich, Anna-Maria, additional, Hansen, Gesine, additional, Kopp, Matthias V., additional, von Mutius, Erika, additional, Rabe, Klaus F., additional, Hohlfeld, Jens M., additional, and Bahmer, Thomas, additional
- Published
- 2020
- Full Text
- View/download PDF
19. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study
- Author
-
Waschki, Benjamin, primary, Alter, Peter, additional, Zeller, Tanja, additional, Magnussen, Christina, additional, Neumann, Johannes T., additional, Twerenbold, Raphael, additional, Sinning, Christoph, additional, Herr, Christian, additional, Kahnert, Kathrin, additional, Fähndrich, Sebastian, additional, Blankenberg, Stefan, additional, Rabe, Klaus F., additional, Welte, Tobias, additional, Jörres, Rudolf A., additional, Vogelmeier, Claus F., additional, Bals, Robert, additional, and Watz, Henrik, additional
- Published
- 2019
- Full Text
- View/download PDF
20. CAT score single item analysis in patients with COPD: Results from COSYCONET
- Author
-
Marietta von Siemens, Sarah, primary, Alter, Peter, additional, Lutter, Johanna I., additional, Kauczor, Hans-Ulrich, additional, Jobst, Bertram, additional, Bals, Robert, additional, Trudzinski, Franziska C., additional, Söhler, Sandra, additional, Behr, Jürgen, additional, Watz, Henrik, additional, Waschki, Benjamin, additional, Bewig, Burkhard, additional, Jones, Paul W., additional, Welte, Tobias, additional, Vogelmeier, Claus F., additional, Jörres, Rudolf A., additional, Kahnert, Kathrin, additional, Stefan, Andreas, additional, Robert, Bals, additional, Jürgen, Behr, additional, Kathrin, Kahnert, additional, Burkhard, Bewig, additional, Roland, Buhl, additional, Ralf, Ewert, additional, Beate, Stubbe, additional, Ficker, Joachim H., additional, Manfred, Gogol, additional, Christian, Grohé, additional, Rainer, Hauck, additional, Matthias, Held, additional, Berthold, Jany, additional, Markus, Henke, additional, Felix, Herth, additional, Gerd, Höffken, additional, Katus Hugo, A., additional, Anne-Marie, Kirsten, additional, Henrik, Watz, additional, Rembert, Koczulla, additional, Klaus, Kenn, additional, Juliane, Kronsbein, additional, Cornelia, Kropf-Sanchen, additional, Christoph, Lange, additional, Peter, Zabel, additional, Michael, Pfeifer, additional, Randerath Winfried, J., additional, Werner, Seeger, additional, Michael, Studnicka, additional, Christian, Taube, additional, Helmut, Teschler, additional, Hartmut, Timmermann, additional, Christian, Virchow J., additional, Claus, Vogelmeier, additional, Ulrich, Wagner, additional, Tobias, Welte, additional, Hubert, Wirtz, additional, Lehnert, Doris, additional, Struck, Birte, additional, Krabbe, Lenka, additional, Arikan, Barbara, additional, Tobias, Julia, additional, Speth, Kornelia, additional, Pieper, Jeanette, additional, Gleiniger, Margret, additional, Markworth, Britta, additional, Hinz, Zaklina, additional, Burmann, Ellen, additional, Wons, Katrin, additional, Rieber, Ulrike, additional, Schaufler, Beate, additional, Schwedler, Katrin, additional, Michalewski, Sabine, additional, Rohweder, Sonja, additional, Berger, Patricia, additional, Schottel, Diana, additional, Janke, Vivien, additional, Untsch, Rosalie, additional, Graf, Jana, additional, Reichel, Anita, additional, Weiß, Gertraud, additional, Traugott, Erich, additional, Kietzmann, Ilona, additional, Schrade-Illmann, Michaela, additional, Polte, Beate, additional, and Hübner, Gudrun, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity: A Cross-sectional Study
- Author
-
Watz, Henrik, Waschki, Benjamin, Boehme, Corinna, Claussen, Martin, Meyer, Thorsten, and Magnussen, Helgo
- Published
- 2008
- Full Text
- View/download PDF
22. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort
- Author
-
Alter, Peter, Mayerhofer, Barbara A, Kahnert, Kathrin, Watz, Henrik, Waschki, Benjamin, Andreas, Stefan, Biertz, Frank, Bals, Robert, Vogelmeier, Claus F, and Jörres, Rudolf A
- Subjects
Male ,Heart Diseases ,heart failure ,dyspnea ,Middle Aged ,International Journal of Chronic Obstructive Pulmonary Disease ,COPD ,echocardiography ,medication ,symptoms ,respiratory tract diseases ,Cohort Studies ,Pulmonary Disease, Chronic Obstructive ,Prevalence ,Humans ,Female ,Original Research ,Aged - Abstract
Peter Alter,1 Barbara A Mayerhofer,2 Kathrin Kahnert,3 Henrik Watz,4 Benjamin Waschki,5,6 Stefan Andreas,7,8 Frank Biertz,9 Robert Bals,10 Claus F Vogelmeier,1 Rudolf A Jörres2 1Department of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Marburg, Germany; 2Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the Center for Lung Research (DZL), Munich, Germany; 3Department of Internal Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany; 4Pulmonary Research Institute at Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; 5Department of Pneumology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; 6Department of General and Interventional Cardiology, University Heart Center, Hamburg, Germany; 7Department of Cardiology and Pneumology, University Medical Center, Goettingen, Germany; 8Lung Clinic, Immenhausen, Germany; 9Institute for Biostatistics, Center for Biometry, Medical Informatics and Medical Technology, Hannover Medical School, Hannover, Germany; 10Department of Internal Medicine V - Pulmonology, Allergology, Intensive Care Medicine, Saarland University Hospital, Homburg, GermanyCorrespondence: Peter AlterDepartment of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Baldingerstrasse 1, Marburg 35033, GermanyTel +49 6 421 586 6140Email Alter@uni-marburg.de Rudolf A JörresInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the Center for Lung Research (DZL), Ziemssenstrasse 1, Munich 80336, GermanyTel +49 8 944 005 2466Email Rudolf.Joerres@med.uni-muenchen.de 򠮬kground: A substantial prevalence of cardiovascular disease is known for COPD, but detection of its presence, relationship to functional findings and contribution to symptoms remains challenging. The present analysis focusses on the cardiovascular contribution to COPD symptoms and their relationship to the patients’ diagnostic status, medication and echocardiographic findings.Methods: Patients from the COPD cohort COSYCONET with data on lung function, including FEV1, residual volume/total lung capacity (RV/TLC) ratio, diffusing capacity TLCO, and echocardiographic data on left ventricular ejection fraction (LVEF) and end-diastolic diameter (LVEDD), medical history, medication, modified British Medical Research Council dyspnea scale (mMRC) and Saint Georges Respiratory Questionnaire (SGRQ) were analyzed.Results: A total of 1591 patients (GOLD 0–4: n=230/126/614/498/123) fulfilled the inclusion criteria. Ischemic heart disease, myocardial infarction or heart failure were reported in 289 patients (18.2%); 860 patients (54%) received at least one cardiovascular medication, with more than one in many patients. LVEF56 mm was found in 204 patients (12.8%), of whom 74 (36.3%) had neither a cardiovascular history nor medication. Among 948 patients (59.6%) without isolated hypertension, there were 21/55 (38.2%) patients with LVEF56 mm, who lacked both a cardiac diagnosis and medication. LVEDD and LVEF were linked to medical history; LVEDD was dependent on RV/TLC and LVEF on FEV1. Exertional COPD symptoms were best described by mMRC and the SGRQ activity score. Beyond lung function, an independent link from LVEDD on symptoms was revealed.Conclusion: A remarkable proportion of patients with suspicious echocardiographic findings were undiagnosed and untreated, implying an increased risk for an unfavorable prognosis. Cardiac size and function were dependent on lung function and only partially linked to cardiovascular history. Although the contribution of LV size to COPD symptoms was small compared to lung function, it was detectable irrespective of all other influencing factors. However, only the mMRC and SGRQ activity component were found to be suitable for this purpose.Keywords: COPD, heart failure, echocardiography, medication, dyspnea, symptoms
- Published
- 2019
23. Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils
- Author
-
Pedersen, Frauke, primary, Waschki, Benjamin, additional, Marwitz, Sebastian, additional, Goldmann, Torsten, additional, Kirsten, Anne, additional, Malmgren, Anna, additional, Rabe, Klaus F., additional, Uddin, Mohib, additional, and Watz, Henrik, additional
- Published
- 2018
- Full Text
- View/download PDF
24. Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients
- Author
-
Pedersen, Frauke, Marwitz, Sebastian, Holz, Olaf, Kirsten, Anne, Bahmer, Thomas, Waschki, Benjamin, Magnussen, Helgo, Rabe, Klaus F., Goldmann, Torsten, Uddin, Mohib, and Watz, Henrik
- Published
- 2015
- Full Text
- View/download PDF
25. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis
- Author
-
Bahmer, Thomas, primary, Kirsten, Anne-Marie, additional, Waschki, Benjamin, additional, Rabe, Klaus F., additional, Magnussen, Helgo, additional, Kirsten, Detlef, additional, Gramm, Marco, additional, Hummler, Simone, additional, Brunnemer, Eva, additional, Kreuter, Michael, additional, and Watz, Henrik, additional
- Published
- 2017
- Full Text
- View/download PDF
26. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
- Author
-
Waschki, Benjamin, primary, Watz, Henrik, additional, Holz, Olaf, additional, Magnussen, Helgo, additional, Olejnicka, Beata, additional, Welte, Tobias, additional, Rabe, Klaus F, additional, and Janciauskiene, Sabina, additional
- Published
- 2017
- Full Text
- View/download PDF
27. Physical activity patterns and clusters in 1001 patients with COPD
- Author
-
Mesquita, Rafael, primary, Spina, Gabriele, additional, Pitta, Fabio, additional, Donaire-Gonzalez, David, additional, Deering, Brenda M, additional, Patel, Mehul S, additional, Mitchell, Katy E, additional, Alison, Jennifer, additional, van Gestel, Arnoldus JR, additional, Zogg, Stefanie, additional, Gagnon, Philippe, additional, Abascal-Bolado, Beatriz, additional, Vagaggini, Barbara, additional, Garcia-Aymerich, Judith, additional, Jenkins, Sue C, additional, Romme, Elisabeth APM, additional, Kon, Samantha SC, additional, Albert, Paul S, additional, Waschki, Benjamin, additional, Shrikrishna, Dinesh, additional, Singh, Sally J, additional, Hopkinson, Nicholas S, additional, Miedinger, David, additional, Benzo, Roberto P, additional, Maltais, François, additional, Paggiaro, Pierluigi, additional, McKeough, Zoe J, additional, Polkey, Michael I, additional, Hill, Kylie, additional, Man, William D-C, additional, Clarenbach, Christian F, additional, Hernandes, Nidia A, additional, Savi, Daniela, additional, Wootton, Sally, additional, Furlanetto, Karina C, additional, Cindy Ng, Li W, additional, Vaes, Anouk W, additional, Jenkins, Christine, additional, Eastwood, Peter R, additional, Jarreta, Diana, additional, Kirsten, Anne, additional, Brooks, Dina, additional, Hillman, David R, additional, Sant’Anna, Thaís, additional, Meijer, Kenneth, additional, Dürr, Selina, additional, Rutten, Erica PA, additional, Kohler, Malcolm, additional, Probst, Vanessa S, additional, Tal-Singer, Ruth, additional, Gil, Esther Garcia, additional, den Brinker, Albertus C, additional, Leuppi, Jörg D, additional, Calverley, Peter MA, additional, Smeenk, Frank WJM, additional, Costello, Richard W, additional, Gramm, Marco, additional, Goldstein, Roger, additional, Groenen, Miriam TJ, additional, Magnussen, Helgo, additional, Wouters, Emiel FM, additional, ZuWallack, Richard L, additional, Amft, Oliver, additional, Watz, Henrik, additional, and Spruit, Martijn A, additional
- Published
- 2017
- Full Text
- View/download PDF
28. Physical activity, airway resistance and small airway dysfunction in severe asthma
- Author
-
Bahmer, Thomas, primary, Waschki, Benjamin, additional, Schatz, Fee, additional, Herzmann, Christian, additional, Zabel, Peter, additional, Kirsten, Anne-Marie, additional, Rabe, Klaus F., additional, and Watz, Henrik, additional
- Published
- 2016
- Full Text
- View/download PDF
29. An official European Respiratory Society statement on physical activity in COPD
- Author
-
Watz, Henrik, primary, Pitta, Fabio, additional, Rochester, Carolyn L., additional, Garcia-Aymerich, Judith, additional, ZuWallack, Richard, additional, Troosters, Thierry, additional, Vaes, Anouk W., additional, Puhan, Milo A., additional, Jehn, Melissa, additional, Polkey, Michael I., additional, Vogiatzis, Ioannis, additional, Clini, Enrico M., additional, Toth, Michael, additional, Gimeno-Santos, Elena, additional, Waschki, Benjamin, additional, Esteban, Cristobal, additional, Hayot, Maurice, additional, Casaburi, Richard, additional, Porszasz, Janos, additional, McAuley, Edward, additional, Singh, Sally J., additional, Langer, Daniel, additional, Wouters, Emiel F.M., additional, Magnussen, Helgo, additional, and Spruit, Martijn A., additional
- Published
- 2014
- Full Text
- View/download PDF
30. Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD
- Author
-
Holz, Olaf, primary, Waschki, Benjamin, additional, Roepcke, Stefan, additional, Watz, Henrik, additional, Lauer, Gereon, additional, Faulenbach, Cornelia, additional, and Hohlfeld, Jens M, additional
- Published
- 2014
- Full Text
- View/download PDF
31. Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity
- Author
-
Cockayne, Debra A., primary, Cheng, Donavan T., additional, Waschki, Benjamin, additional, Sridhar, Sriram, additional, Ravindran, Palanikumar, additional, Hilton, Holly, additional, Kourteva, Galina, additional, Bitter, Hans, additional, Pillai, Sreekumar G., additional, Visvanathan, Sudha, additional, Müller, Kai-Christian, additional, Holz, Olaf, additional, Magnussen, Helgo, additional, Watz, Henrik, additional, and Fine, Jay S., additional
- Published
- 2012
- Full Text
- View/download PDF
32. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis
- Author
-
Hermes, Andreas, primary, Gatzemeier, Ulrich, additional, Waschki, Benjamin, additional, and Reck, Martin, additional
- Published
- 2010
- Full Text
- View/download PDF
33. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort.
- Author
-
von Siemens, Sarah Marietta, Perneczky, Robert, Vogelmeier, Claus F., Behr, Jürgen, Kauffmann-Guerrero, Diego, Alter, Peter, Trudzinski, Franziska C., Bals, Robert, Grohé, Christian, Söhler, Sandra, Waschki, Benjamin, Lutter, Johanna I., Welte, Tobias, Jörres, Rudolf A., Kahnert, Kathrin, the COSYCONET study group, Andreas, Stefan, Bewig, Burkhard, Buhl, Roland, and Ewert, Ralf
- Subjects
COGNITIVE ability ,COGNITION disorders ,PATH analysis (Statistics) ,MONTREAL Cognitive Assessment ,OXYGEN in the blood ,CHARACTERISTIC functions ,BLOOD lactate - Abstract
Alterations of cognitive functions have been described in COPD. Our study aimed to disentangle the relationship between the degree of cognitive function and COPD characteristics including quality of life (QoL).Data from 1969 COPD patients of the COSYCONET cohort (GOLD grades 1-4; 1216 male/ 753 female; mean (SD) age 64.9 ± 8.4 years) were analysed using regression and path analysis. The DemTect screening tool was used to measure cognitive function, and the St. George's respiratory questionnaire (SGRQ) to assess disease-specific QoL.DemTect scores were < 9 points in 1.6% of patients and < 13 points in 12% when using the original evaluation algorithm distinguishing between < 60 or > =60 years of age. For statistical reasons, we used the average of both algorithms independent of age in all subsequent analyses. The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. Conversely, the SGRQ impact score was independently associated with 6-MWD, FVC, mMRC and DemTect. These results were combined into a path analysis model to account for direct and indirect effects. The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. Furthermore, a reduction in cognitive capacity was associated with reduced disease-specific quality of life. As a potential clinical implication of this work, we suggest to screen especially patients with low oxygen content and low 6-MWD for cognitive impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis
- Author
-
Jilles M Fermont, Jacob M Marott, Katya L Masconi, Valéria Amorim Pires Di Lorenzo, Renata Ferrari, Hana Müllerová, Magnus T. Jensen, Angela M. Wood, Michael I. Polkey, Benjamin Waschki, Henrik Watz, Philipp Schuetz, Ian B. Wilkinson, Waschki, Benjamin [0000-0002-1070-3661], and Apollo - University of Cambridge Repository
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Exacerbation ,Chronic Obstructive Pulmonary Disease ,Severity of Illness Index ,Pulmonary Disease, Chronic Obstructive ,Internal medicine ,Epidemiology ,Heart rate ,medicine ,Risk of mortality ,Humans ,copd epidemiology ,Pulse wave velocity ,COPD ,biology ,business.industry ,C-reactive protein ,Hemodynamics ,medicine.disease ,Respiratory Function Tests ,Meta-analysis ,biology.protein ,Exercise Test ,business ,Biomarkers - Abstract
BackgroundConventional measures to evaluate COPD may fail to capture systemic problems, particularly musculoskeletal weakness and cardiovascular disease. Identifying these manifestations and assessing their association with clinical outcomes (ie, mortality, exacerbation and COPD hospital admission) is of increasing clinical importance.ObjectiveTo assess associations between 6 min walk distance (6MWD), heart rate, fibrinogen, C reactive protein (CRP), white cell count (WCC), interleukins 6 and 8 (IL-6 and IL-8), tumour necrosis factor-alpha, quadriceps maximum voluntary contraction, sniff nasal inspiratory pressure, short physical performance battery, pulse wave velocity, carotid intima-media thickness and augmentation index and clinical outcomes in patients with stable COPD.MethodsWe systematically searched electronic databases (August 2018) and identified 61 studies, which were synthesised, including meta-analyses to estimate pooled HRs, following Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.ResultsShorter 6MWD and elevated heart rate, fibrinogen, CRP and WCC were associated with higher risk of mortality. Pooled HRs were 0.80 (95% CI 0.73 to 0.89) per 50 m longer 6MWD, 1.10 (95% CI 1.02 to 1.18) per 10 bpm higher heart rate, 3.13 (95% CI 2.14 to 4.57) per twofold increase in fibrinogen, 1.17 (95% CI 1.06 to 1.28) per twofold increase in CRP and 2.07 (95% CI 1.29 to 3.31) per twofold increase in WCC. Shorter 6MWD and elevated fibrinogen and CRP were associated with exacerbation, and shorter 6MWD, higher heart rate, CRP and IL-6 were associated with hospitalisation. Few studies examined associations with musculoskeletal measures.ConclusionFindings suggest 6MWD, heart rate, CRP, fibrinogen and WCC are associated with clinical outcomes in patients with stable COPD. Use of musculoskeletal measures to assess outcomes in patients with COPD requires further investigation.Trial registration numberCRD42016052075.
- Published
- 2019
35. IgA + memory B-cells are significantly increased in patients with asthma and small airway dysfunction.
- Author
-
Habener A, Grychtol R, Gaedcke S, DeLuca D, Dittrich AM, Happle C, Abdo M, Watz H, Pedersen F, König IR, Thiele D, Kopp MV, von Mutius E, Bahmer T, Rabe KF, Meyer-Bahlburg A, Hansen G, Fuchs O, Roesler B, Welchering N, Kohistani-Greif N, Kurz J, Landgraf-Rauf K, Laubhahn K, Maison N, Liebl C, Schaub B, Ege M, Illi S, Hose A, Zeitlmann E, Berbig M, Marzi C, Schauberger C, Zissler U, Schmidt-Weber C, Ricklefs I, Diekmann G, Liboschik L, Voigt G, Sultansei L, Weckmann M, Nissen G, Kirsten AM, Waschki B, Herzmann C, Biller H, Gaede KI, Bovermann X, Steinmetz A, Husstedt BL, Nitsche C, Veith V, Szewczyk M, Brinkmann F, Malik A, Schwerk N, Dopfer C, Price M, Jirmo AC, Liu B, Calveron MR, Weber S, Foth S, Skevaki C, Renz H, Meyer M, Schildberg T, Rietschel E, van Koningsbruggen-Rietschel S, and Alcazar M
- Subjects
- Adult, Humans, Spirometry, Oscillometry, Respiratory System, Immunoglobulin A, Asthma
- Abstract
Background: Comprehensive studies investigated the role of T-cells in asthma which led to personalised treatment options targeting severe eosinophilic asthma. However, little is known about the contribution of B-cells to this chronic inflammatory disease. In this study we investigated the contribution of various B-cell populations to specific clinical features in asthma., Methods: In the All Age Asthma Cohort (ALLIANCE), a subgroup of 154 adult asthma patients and 28 healthy controls were included for B-cell characterisation by flow cytometry. Questionnaires, lung function measurements, blood differential counts and allergy testing of participants were analysed together with comprehensive data on B-cells using association studies and multivariate linear models., Results: Patients with severe asthma showed decreased immature B-cell populations while memory B-cells were significantly increased compared with both mild-moderate asthma patients and healthy controls. Furthermore, increased frequencies of IgA
+ memory B-cells were associated with impaired lung function and specifically with parameters indicative for augmented resistance in the peripheral airways. Accordingly, asthma patients with small airway dysfunction (SAD) defined by impulse oscillometry showed increased frequencies of IgA+ memory B-cells, particularly in patients with mild-moderate asthma. Additionally, IgA+ memory B-cells significantly correlated with clinical features of SAD such as exacerbations., Conclusions: With this study we demonstrate for the first time a significant association of increased IgA+ memory B-cells with asthma and SAD, pointing towards future options for B-cell-directed strategies in preventing and treating asthma., Competing Interests: Conflict of interest: C. Happle reports grants from Novartis and Pari, outside the submitted work. M.V. Kopp reports grants from Allergopharma GmbH and Vertex GmbH; honoraria for lectures from Allergopharma GmbH, Sanofi GmbH, Infectopharm GmbH, Vertex GmbH and Leti GmbH; advisory board membership at Allergopharma GmbH and Sanofi GmbH; outside the submitted work. E. von Mutius reports royalties from Elsevier GmbH, Georg Thieme Verlag, Springer-Verlag GmbH and Elsevier Ltd; consulting fees from the Chinese University of Hong Kong, European Commission, HiPP GmbH & Co KG and AstraZeneca; lecture honoraria from Massachusetts Medical Society, Springer-Verlag GmbH, Elsevier Ltd, Boehringer Ingelheim International GmbH, European Respiratory Society, Universiteit Utrecht – Faculteit Diergeneeskunde, Universität Salzburg, Springer Medizin Verlag GmbH, Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI), Klinikum Rechts der Isar, University of Colorado, Paul-Martini-Stiftung and Imperial College London; travel support from Verein zur Förderung der Pneumologie am Krankenhaus Großhansdorf eV, Pneumologie Développement, Mondial Congress & Events GmbH & Co. KG, American Academy of Allergy, Asthma & Immunology, Imperial College London, Margaux Orange, Volkswagen Stiftung, Boehringer Ingelheim International GmbH, European Respiratory Society, Universiteit Utrecht – Faculteit Diergeneeskunde, Österreichische Gesellschaft für Allergologie und Immunologie, Massachusetts Medical Society, OM Pharma SA, Hanson Wade Ltd, iKOMM GmbH, DSI Dansk Borneastma Center, American Thoracic Society, HiPP GmbH & Co. KG and Universiteit Utrecht – Faculteit Bètawetenschappen; outside the submitted work. In addition, E. von Mutius has patent LU101064 (Barn dust extract for the prevention and treatment of diseases) pending, royalties paid to ProtectImmun for patent EP2361632 (Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders, granted on 19 March 2014), and patents EP1411977 (Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases, granted on 18 April 2007), EP1637147 (Stable dust extract for allergy protection, granted on 10 December 2008) and EP1964570 (Pharmaceutical compound to protect against allergies and inflammatory diseases, granted on 21 November 2012) licensed to ProtectImmun. In addition, E. von Mutius is a member of the EXPANSE (funded by European Commission) Scientific Advisory Board, member of the BEAMS External Scientific Advisory Board (ESAB), member of the Editorial Board of the Journal of Allergy and Clinical Immunology: In Practice, member of the Scientific Advisory Board of the Children's Respiratory and Environmental Workgroup (CREW), member of the International Scientific and Societal Advisory Board (ISSAB) of Utrecht Life Sciences (ULS), University of Utrecht, member of the External Review Panel of the Faculty of Veterinary Science, University of Utrecht, member of the Selection Committee for the Gottfried Wilhelm Leibniz Programme (DFG), member of the International Advisory Board of the Asthma UK Centre for Applied Research (AUKCAR), member of the International Advisory Board of The Lancet Respiratory Medicine, and member of the Scientific Advisory Board of the CHILD (Canadian Healthy Infant Longitudinal Development) study, McMaster University, Hamilton, Canada. T. Bahmer reports grants from Network University Medicine (NUM): National Pandemic Cohort Network (NAPKON); consulting fees and lecture honoraria from AstraZeneca, Novartis, GlaxoSmithKline, Roche and Chiesi; travel support from Chiesi and AstraZeneca; outside the submitted work. K.F. Rabe reports lecture honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Novartis, Sanofi Regeneron, GlaxoSmithKline, Berlin-Chemie and Roche; advisory board membership at AstraZeneca and Sanofi Regeneron; leadership roles with the German Center for Lung Research (DZL), German Chest Society (DGP) and American Thoracic Society; outside the submitted work. A. Meyer-Bahlburg reports lecture honoraria from Pfizer; travel support from CSL Behring; advisory board membership with Pfizer; outside the submitted work. G. Hansen reports consulting fees from Sanofi GmbH; lecture honoraria from MedUpdate and AbbVie; outside the submitted work. All other authors have nothing to disclose., (Copyright ©The authors 2022.)- Published
- 2022
- Full Text
- View/download PDF
36. T2-high asthma phenotypes across lifespan.
- Author
-
Maison N, Omony J, Illi S, Thiele D, Skevaki C, Dittrich AM, Bahmer T, Rabe KF, Weckmann M, Happle C, Schaub B, Meyer M, Foth S, Rietschel E, Renz H, Hansen G, Kopp MV, von Mutius E, Grychtol R, Fuchs O, Roesler B, Welchering N, Kohistani-Greif N, Kurz J, Landgraf-Rauf K, Laubhahn K, Liebl C, Ege M, Hose A, Zeitlmann E, Berbig M, Marzi C, Schauberger C, Zissler U, Schmidt-Weber C, Ricklefs I, Diekmann G, Liboschik L, Voigt G, Sultansei L, Nissen G, König IR, Kirsten AM, Pedersen F, Watz H, Waschki B, Herzmann C, Abdo M, Biller H, Gaede KI, Bovermann X, Steinmetz A, Husstedt BL, Nitsche C, Veith V, Szewczyk M, Brinkmann F, Malik A, Schwerk N, Dopfer C, Price M, Jirmo AC, Habener A, DeLuca DS, Gaedcke S, Liu B, Calveron MR, Weber S, Schildberg T, van Koningsbruggen-Rietschel S, and Alcazar M
- Subjects
- Allergens, Biomarkers, CD28 Antigens genetics, Eosinophils, Humans, Immunoglobulin E, Interleukin-13, Interleukin-5, Lipopolysaccharides, Longevity, Phenotype, Asthma, Eosinophilia
- Abstract
Rationale: In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children., Objectives: To define T2-high asthma with easily accessible biomarkers and compare resulting phenotypes across all ages., Methods: In the multicentre clinical All Age Asthma Cohort (ALLIANCE), 1125 participants (n=776 asthmatics, n=349 controls) were recruited and followed for 2 years (1 year in adults). Extensive clinical characterisation (questionnaires, blood differential count, allergy testing, lung function and sputum induction (in adults)) was performed at baseline and follow-ups. Interleukin (IL)-4, IL-5 and IL-13 were measured after stimulation of whole blood with lipopolysaccharide (LPS) or anti-CD3/CD28., Measurements and Main Results: Based on blood eosinophil counts and allergen-specific serum IgE antibodies, patients were categorised into four mutually exclusive phenotypes: "atopy-only", "eosinophils-only", "T2-high" (eosinophilia + atopy) and "T2-low" (neither eosinophilia nor atopy). The T2-high phenotype was found across all ages, even in very young children in whom it persisted to a large degree even after 2 years of follow-up. T2-high asthma in adults was associated with childhood onset, suggesting early origins of this asthma phenotype. In both children and adults, the T2-high phenotype was characterised by excessive production of specific IgE to allergens (p<0.0001) and, from school age onwards, by increased production of IL-5 after anti-CD3/CD28 stimulation of whole blood., Conclusions: Using easily accessible biomarkers, patients with T2-high asthma can be identified across all ages delineating a distinct phenotype. These patients may benefit from therapy with biologicals even at a younger age., Competing Interests: Conflict of interest: N. Maison, J. Omony, S. Illi, D. Thiele, A.M. Dittrich, C. Happle, M. Meyer, S. Foth and R. Grychtol have nothing to disclose. C. Skevaki reports grants and personal fees from Hycor Biomedical, Bencard Allergie, Thermo Fisher Scientific as well as grants from Mead Johnson Nutrition (MJN), Universities Giessen and Marburg Lung Centre, the German Centre for Lung Research (DZL), University Hospital Giessen and Marburg, Deutsche Forschungsgemeinschaft (DFG). T. Bahmer reports grants from the Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL) and personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Roche and Chiesi. M. Weckmann reports grants from Federal Ministry for Education and Research (BMBF), University of Luebeck and German Academic Exchange Service. B. Schaub reports grants from DFG, BMBF, the EU as well from GlaxoSmithKline, Sanofi and Novartis. H. Renz reports grants from German Center for Lung Disease (DZL) and Universities Giessen Marburg Lung Center. M.V. Kopp reports grants and personal fees from Allergopharma GmbH and Vertex GmbH; additional, personal fees from Sanofi GmbH, Infectopharm GmbH and Leti GmbH. E. Rietschel reports personal lecture payments for Nutricia Milupa GmbH and Novartis Pharma, and honoraria for participation in advisory boards for MICE-Mylan, Novartis Pharma GmbH and Boehringer Ingelheim GmbH. K.F. Rabe recieved personal payments or honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Novartis, Sanofi & Regeneron, GlaxoSmithKline, Berlin Chemie and Roche; K.F. Rabe also discloses participation on data safety monitoring boards/advisory boards for AstraZeneca and Sanofi Regeneron, and leadership or fiduciary role in the German Center for Lung Research (DZL), German Chest Society (DGP) and American Thoracic Society (ATS). G. Hansen reports grants from German Federal Ministry of Education and Research (BMBF) and German Research Foundation (DFG) as well as personal fees from Sanofi GmbH, MedUpdate, and Abbvie. E. von Mutius reports grants from the German Center for Lung Research (DZL) as well as royalties/licenses held by Elsevier GmbH, Gerog Thieme Verlag, Springer Verlag GmbH, Elsevier Ltd; furthermore, consultation fees were received from the Chinese University of Hong Kong, European Commission, HiPP GmbH and AstraZeneca; E. von Mutius also received payments and/or support for meetings/travel from the Massachusetts Medical Society, Springer-Verlag GmbH, Elsevier Ltd, Böhringer Ingelheim International GmbH, European Respiratory Society (ERS), University Utrecht, Salzburg, Colorado and Imperial College London, Springer Medizin Verlag GmbH, Japanese Society of Pediatric Allergy and Clinical Immunology, Klinkum Rechts der Isar, Paul-Martini-Stiftung; further support for meetings/travel was granted by Verein zur Förderung der Pneumologie am Krankenhaus Groshansdorf, Pneumologie Development Mondial Congress & Events GmbH, American Academy of Allergy, Asthma & Immunology, Margaux Orange, Volkswagen Stiftung, Österreichische Gesellschaft für Allergologie & Immunologie, OM Pharma SA, Hanson Wade Ltd, iKOMM GmbH, DSI Dansk Bornestma Center, American Thoracic Society, HiPP GmbH; E. von Mutius has patent EP2361632, EP1411977, EP1637147 and EP 1964570 (licensed to Protectimmun), furthermore patent LU101064 is pending; E. von Mutius participates in the following data monitoring or advisory boards: EXPANSE, BEAMS External Scientific Advisory Board, Journal of Allergy and Clinical Immunology: in Practice, Children's Respiratory and Environmental Workgroup (CREW), International Scientific & Societal Advisory Board of Utrecht Life Sciences, External Review Panel of the Faculty of Veterinary Science (University of Utrecht), Gottfried Wilhelm Leibniz Programme, Asthma UK for Applied Research, Advisory Board of The Lancet Respiratory Medicine, CHILD (Canadian Healthy Infant Longitudinal Development Study)., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
37. Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort.
- Author
-
Holz O, Waschki B, Watz H, Kirsten A, Abdo M, Pedersen F, Weckmann M, Fuchs O, Dittrich AM, Hansen G, Kopp MV, von Mutius E, Rabe KF, Hohlfeld JM, and Bahmer T
- Subjects
- Adult, Biomarkers, Breath Tests, Exhalation, Humans, Negative Results, Asthma, Volatile Organic Compounds
- Abstract
Competing Interests: Conflict of interest: O. Holz has nothing to disclose. Conflict of interest: B. Waschki has nothing to disclose. Conflict of interest: H. Watz has nothing to disclose. Conflict of interest: A. Kirsten has nothing to disclose. Conflict of interest: M. Abdo has nothing to disclose. Conflict of interest: F. Pedersen has nothing to disclose. Conflict of interest: M. Weckmann has nothing to disclose. Conflict of interest: O. Fuchs has nothing to disclose. Conflict of interest: A-M. Dittrich has nothing to disclose. Conflict of interest: G. Hansen reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study. Conflict of interest: M.V. Kopp reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study; personal fees for lectures and consultancy from ALK-Abello, Allergopharma, Chiesi, Meda, Novartis Pharma, Vertex, Abbvie and Infectopharm, grants from Allergopharma and Vertex, outside the submitted work. Conflict of interest: E. von Mutius reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study; authorship fees from Springer-Verlag GmbH, Georg Thieme Verlag and Elsevier Ltd, personal fees for consultancy from HiPP GmbH & Co. KG, OM Pharma SA and Peptinnovate Ltd, personal fees for lectures from Boehringer Ingelheim International GmbH, outside the submitted work; and has a patent LU101064, “Barn dust extract for the prevention and treatment of diseases” pending, a patent EP2361632, “Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders” with royalties paid to ProtectImmun GmbH, a patent number EP 1411977, “Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases” licensed to ProtectImmun GmbH, a patent EP1637147, “Stable dust extract for allergy protection” licensed to ProtectImmun GmbH, and a patent EP 1964570, “Pharmaceutical compound to protect against allergies and inflammatory diseases” licensed to ProtectImmun GmbH. Conflict of interest: K.F. Rabe reports grants and personal fees from Boehringer Ingelheim and AstraZeneca, personal fees from Novartis, Sanofi, Regeneron, Roche and Chiesi Pharmaceuticals outside the submitted work. Conflict of interest: J.M. Hohlfeld reports grants from German Ministry for Education and Research (BMBF; grant DZL 2016-2020/82DZL002A2), during the conduct of the study; personal fees for consultancy from Boehringer Ingelheim and Merck & Co., Inc., personal fees for lectures from Novartis and HAL, grants from AstraZeneca AB, Novartis, Janssen Pharmaceutica NV, ALK, Boehringer Ingelheim, LETI, GlaxoSmithKline, Sanofi-Aventis, Astellas Pharma and Allergopharma, outside the submitted work. Conflict of interest: T. Bahmer reports grants from BMBF (unrestricted research grant for the German Center for Lung Research, DZL), during the conduct of the study; personal fees lectures and consultancy, and compensation of travel expenses from AstraZeneca, GlaxoSmithKline, Novartis and Roche, outside the submitted work.
- Published
- 2021
- Full Text
- View/download PDF
38. Physical activity, airway resistance and small airway dysfunction in severe asthma.
- Author
-
Bahmer T, Waschki B, Schatz F, Herzmann C, Zabel P, Kirsten AM, Rabe KF, and Watz H
- Subjects
- Adult, Aged, Case-Control Studies, Female, Germany, Humans, Male, Middle Aged, Oscillometry, Plethysmography, Prospective Studies, Pulmonary Disease, Chronic Obstructive, Spirometry, Airway Resistance, Asthma physiopathology, Exercise, Lung physiopathology
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.